Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context | Zendy

MéndezLucio Oscar | Zendy; Tran Jeremy | Zendy; MedinaFranco José L. | Zendy; Meurice Nathalie | Zendy; Muller Mark | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Toward Drug Repurposing in Epigenetics: Olsalazine as a Hypomethylating Compound Active in a Cellular Context

Author(s) -

MéndezLucio Oscar,

Tran Jeremy,

MedinaFranco José L.,

Meurice Nathalie,

Muller Mark

Publication year - 2014

Publication title -

chemmedchem

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.817

H-Index - 100

eISSN - 1860-7187

pISSN - 1860-7179

DOI - 10.1002/cmdc.201300555

Subject(s) - hypomethylating agent , drug repositioning , epigenetics , context (archaeology) , drug , dna methylation , methyltransferase , pharmacology , dna , computational biology , biology , methylation , biochemistry , gene , paleontology , gene expression

DNA hypomethylating drugs that act on DNA methyltransferase (DNMT) isoforms are promising anticancer agents. By using a well‐characterized live‐cell system to measure DNA methylation revisions (imprints), we characterize olsalazine, an approved anti‐inflammatory drug, as a novel DNA hypomethylating agent. The cell‐based screen used in this work is highly tractable, internally controlled, and well‐suited for a drug repurposing strategy in epigenetics. Olsalazine very closely mimics the action of 5‐aza‐2′‐deoxycytidine, a known hypomethylating drug, with minimal cytotoxicity at the concentrations tested. Olsalazine was identified by a rapid computer‐guided similarity search of a database of approved drugs to a previously identified inhibitor of DNMTs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research